Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | TYMS | P04818 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | TLR4 | O00206 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminopterin SCHEMBL1626034 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL8887 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29443569 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL29398079 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL9514067 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL20769794 | 1.00 | DHFR (0.76) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL23581239 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL5024596 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL2504074 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Aminopterin SCHEMBL2387187 | 0.99 | DHFR (0.75) | DHFRKDM4EMEN1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110302004-A | Device and method for ocular injection | 科尼尔赛德生物医学公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | AVEXXIN AS (NO) | 2019-07-18 | — | — | US | disclosed |
| CN-109219451-A | Conjoint therapy comprising how unsaturated ketone and folic acid gametophyte | 埃维克辛公司 | 2019-01-15 | — | — | CN | disclosed |
| CN-108430492-A | Single-stranded CD27 receptor agonist proteins | 阿珀吉科吉尼科斯股份公司 | 2018-08-21 | — | — | CN | disclosed |
| WO-2018037120-A1 | PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER | DANMARKS TEKNISKE UNIVERSITET (DK) | 2018-03-01 | — | — | WO | disclosed |
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| CN-105008343-B | Alternatively benzothiophene derivative of property ERs degradation agent and combinations thereof | 诺华股份有限公司 | 2017-12-08 | — | — | CN | disclosed |
| US-20170128452-A1 | Aminopterin Dosage Forms | AMINOPTERIN LLC (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128452-A1 | Aminopterin Dosage Forms | AMINOPTERIN LLC (US) | 2017-05-11 | — | — | US | disclosed |
| CN-1686552-A | Anti-solid tumor pharmaceutical composition containing topoisomerase inhibitor | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | disclosed |
| CN-1679944-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679950-A | Anticarcinogenic internal implant agent | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1634586-A | Anti-cancer medicine composition | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | disclosed |
| US-4925662-A | ANTITUMOR AGENT BONDED TO HUMAN IMMUNOGLOBULIN | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0304481-A4 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS. | UNIV ROCKEFELLER (US) | 1989-07-11 | — | — | EP | disclosed |
| EP-0304481-A1 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS | THE ROCKEFELLER UNIVERSITY (US) | 1989-03-01 | — | — | EP | disclosed |
| WO-1988006620-A1 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS | THE ROCKEFELLER UNIVERSITY (US) | 1988-09-07 | — | — | WO | disclosed |
| US-4738843-A | Anti-tumor substance of immunoglobulin and melphalan and process for producing the same | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0122132-A2 | Anti-tumour substance | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128452-A1 | Aminopterin Dosage Forms | AADAT, TPMT, ANPEP | DHFR 795/4885KDM4E 2884/4885MEN1 1118/4885 |
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | FOLR2, MTHFD2, FOLR1 | DHFR 4/4885KDM4E 2739/4885MEN1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.